ERBB2 and cancer: However, the highest ORR was observed in patients whose cancers had centrally confirmed HER2 IHC positivity (score 3+), including endometrial (84.6%), cervical (75%), ovarian (63.6%), urothelial and biliary tract (56.3%, respectively), and other cancer subtypes (44.4%).